Biogen Inc. (BIIB) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook ...

Biogen will discontinue development of its controversial drug Aduhelm so it can shift efforts to other drugs, including Leqembi, which it developed with Eisai.

Canadian cellulosic ethanol producer Iogen has shipped the first 26,000 gallons of an order for Royal Dutch Shell. Iogen recently announced a deal with Shell that would see them cooperate on ...